|
US2019264265A1
|
|
Compositions and methods for genetic markers to identify risk of oral mucositis
|
|
US2019008881A1
|
|
Compositions and methods for treating muscular dystrophy and other disorders
|
|
US2018207112A1
|
|
Compounds and methods for treating muscular dystrophy and other disorders
|
|
US2018169036A1
|
|
Compositions and methods for treating muscular dystrophy and other disorders
|
|
US2018156784A1
|
|
Immune profiling and minimal residue disease following stem cell transplantation in multiple myeloma
|
|
US2018148796A1
|
|
Methods of determining IMiDS resistance in plasma cell disorders
|
|
US2018120321A1
|
|
Methods and compositions for identifying leukemic stem cells
|
|
US2018080082A1
|
|
Compositions and methods for sjögren's syndrome
|
|
US2017368199A1
|
|
Compositions for treating dystroglycanopathy disorders
|
|
US2018010171A1
|
|
Compositions and methods for oral microbiome signatures
|
|
US2017143468A1
|
|
Intravascular device for hemiarch repair and associated method
|
|
US2015273073A1
|
|
Triazine cationic polymers and methods of use thereof
|
|
US2016192969A1
|
|
System for longitudinal closure of dissected sternums
|
|
AU2012201118A1
|
|
Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
|
